Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

Table 2 Determinants of the plasma aldosterone concentration and aldosterone-to-renin ratio during placebo and during ARB, during a regular sodium intake

	Plasma aldosterone concentration				Aldosterone-to-renin ratio
	Placebo		ARB		Placebo		ARB
	β	P-value	β	P-value	β	P-value	β	P-value
Age (years)	0.011	0.41	0.006	0.67	0.027	0.06	0.350	0.049
Gender (women)	−0.030	0.94	0.492	0.17	0.494	0.22	0.760	0.11
BMI baseline (kg/m²)	0.009	0.81	−0.009	0.80	0.015	0.70	0.029	0.56
Serum sodium (mmol/l)	0.041	0.53	−0.086	0.13	0.034	0.64	0.260	0.74
24 h urinary sodium excretion (mmol/day)	0.001	0.85	−0.002	0.35	<0.001	0.93	−0.003	0.38
Serum potassium (mmol/l)	0.346	0.42	0.011	0.98	0.377	0.42	0.355	0.61
24 h urinary potassium excretion (mmol/day)	−0.001	0.88	−0.003	0.60	<−0.001	>0.99	−0.004	0.64
LN Proteinuria (g/day)	0.078	0.75	−0.135	0.58	0.003	0.99	0.075	0.82
LN Creatinine clearance (ml/min)	−1.213	0.008	−1.090	0.01	−1.215	0.02	−1.475	0.009
LN Active plasma renin concentration (ng AI/ml x h)	0.274	0.29	0.171	0.30

ISSN: 1471-2369